What investor type does AstraZeneca fit best in FoxScore?

AstraZeneca looks fairly balanced in FoxScore: the sub-scores are close to each other. This often fits a diversified approach — then check the metrics (e.g., drawdowns/volatility) to see if they match your risk tolerance.

How meaningful is the available history for AstraZeneca?

AstraZeneca currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.

What is FoxScore good for — and what is it not for?

FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.

Analysis for AstraZeneca

AZN.UK · As of: 02/17/2026

Basic information

Type: Stock

Region: UK

Sector: Health Care

TER: –

History

Available history:15.0 years

Last tradingday:02/17/2026

Description & usage

AstraZeneca is a biopharmaceutical company that researches, develops, manufactures and markets prescription medicines. It generates revenue primarily from selling therapies across multiple disease areas, including oncology and other specialty and chronic conditions. Customers are healthcare systems, hospitals, clinicians and pharmacies across many countries, with pricing and reimbursement frameworks shaping access. A key part of the business is its R&D pipeline, which supports new launches and label expansions over time.

Scale: 0 = weak, 50 = average, 100 = top

Analysis summary

AstraZeneca (AZN.UK) currently has a total score of 71 points, placing it in the strong range. The score is made up of Performance (67), Stability (75) and Trend (77). All three sub-scores are currently above average.

Performance scores 67 points (strong). Key strength: 5Y return at 104.7 %. Even the weakest return is still strong in absolute terms: 3Y return at 32.2 %.

Stability scores 75 points (strong). Best-ranked metric: max drawdown (10Y) at -27.2 %. Main drag: max drawdown (1Y) at -27.2 %. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.

Trend scores 77 points (strong). Key strength: Price is about 25.4 % above SMA200. Even the weakest metric remains solid in absolute terms: 12M momentum at 17.8 %.

Overall, the profile is fairly consistent across dimensions. On a metric level, max drawdown (10Y) stands out, while 3Y return lags.

(Historical evaluation, not investment advice.)

Chart anzeigen

Wenn du fortfährst, wird der Chart von TradingView geladen. Dabei können Daten (z. B. deine IP-Adresse) an TradingView übertragen werden.

Overall score

strong

Scores

Metrics

FAQ

What investor type does AstraZeneca fit best in FoxScore?: AstraZeneca looks fairly balanced in FoxScore: the sub-scores are close to each other. This often fits a diversified approach — then check the metrics (e.g., drawdowns/volatility) to see if they match your risk tolerance.
How meaningful is the available history for AstraZeneca?: AstraZeneca currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
What is FoxScore good for — and what is it not for?: FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.